title: Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Silver
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D014487:Centers for Medicare and Medicaid Services, U.S. / Q000191:economics; D003363:Cost Control; D017277:Drug Approval; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D006278:Medicare / Q000191:economics*; D056687:Off-Label Use; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000191:economics / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000191:economics / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab